Vor Biopharma (VOR)Paradigm Biocapital Advisors LP opened a new position $22.9M

1.75M

Shares reported

0.58%

Disclosed portfolio weight

$22.9M

Reported value

Holdings as of

Dec 31, 2025

Filed

Feb 17, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Dec 31, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 31, 2025, Vor Biopharma Inc. (the “Company”) entered into a separation agreement (the “Separation Agreement”) with Dr. Qing Zuraw, the Company’s Chief Development Officer, as a result of Dr. Zuraw’s decision to pursue other opportunities.”
2. Jan 12, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors

What came next

1. Mar 26, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Vor Biopharma

For Vor Biopharma, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its VOR page.

How this filing works

• SEC Form 13F

Other disclosures at Vor Biopharma

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRFeb 17, 2026
• SEC Form 13F-HRFeb 13, 2026
• SEC Form 13F-HRNov 14, 2025
• SEC Form 4Sep 19, 2025
• SEC Form 4Sep 15, 2025

Everything OQRO holds on this company is on its VOR page.